PD-1在慢性阻塞性肺疾病免疫调节中的作用及治疗潜力
The Role and Therapeutic Potential of PD-1 in the Immune Regulation of Chronic Obstructive Pulmonary Disease
DOI: 10.12677/acm.2026.162566, PDF,    科研立项经费支持
作者: 袁 玺, 徐庚辰, 卫皓阳, 丁 琦, 魏 霞*：西安市第九医院呼吸与危重症医学科，陕西 西安
关键词: 慢性阻塞性肺疾病；PD-1；免疫调控；炎症机制；靶向治疗；Chronic Obstructive Pulmonary Disease； PD-1； Immune Regulation； Inflammatory Mechanism； Targeted Therapy
摘要: 程序性死亡受体-1 (PD-1)是关键的免疫检查点分子，通过与配体PD-L1/PD-L2结合，负向调控T细胞功能，维持免疫稳态。COPD患者中发现PD-1表达上调，与疾病严重程度和急性加重频率相关。其可能通过抑制T细胞功能、促进炎症因子释放及调节免疫细胞活性，参与COPD的慢性炎症和免疫失衡。靶向PD-1/PD-L1通路已成为潜在的治疗策略。通过对PD-1/PD-L1在COPD免疫调控中所发挥作用的综述，进一步阐述PD-1在COPD免疫中的功能。
Abstract: Programmed death receptor-1 (PD-1) is a key immune checkpoint molecule that negatively regulates T cell function by binding to its ligands PD-L1/PD-L2, maintaining immune homeostasis. Upregulated expression of PD-1 has been observed in patients with COPD, which is associated with disease severity and the frequency of acute exacerbations. It may be involved in the chronic inflammation and immune imbalance of COPD by inhibiting T cell function, promoting the release of inflammatory factors, and regulating the activity of immune cells. Targeting the PD-1/PD-L1 pathway has emerged as a potential therapeutic strategy. This review of the role of PD-1/PD-L1 in the immune regulation of COPD further elaborates on the role of PD-1 in the immune function of COPD.
文章引用：袁玺, 徐庚辰, 卫皓阳, 丁琦, 魏霞. PD-1在慢性阻塞性肺疾病免疫调节中的作用及治疗潜力[J]. 临床医学进展, 2026, 16(2): 1733-1741. https://doi.org/10.12677/acm.2026.162566

参考文献

[1] Christenson, S.A., Smith, B.M., Bafadhel, M. and Putcha, N. (2022) Chronic Obstructive Pulmonary Disease. The Lancet, 399, 2227-2242. [Google Scholar] [CrossRef] [PubMed]
[2] 陈典, 隆寰宇, 李姝润, 等. 2024年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学, 2024, 27(13): 1533-1543.
[3] Caramori, G., Casolari, P., Barczyk, A., Durham, A.L., Di Stefano, A. and Adcock, I. (2016) COPD Immunopathology. Seminars in Immunopathology, 38, 497-515. [Google Scholar] [CrossRef] [PubMed]
[4] Tang, Z.S., Hao, Y.H., Zhang, E.J., Xu, C.L., et al. (2016) CD28 Family of Receptors on T Cells in Chronic HBV Infection: Expression Characteristics, Clinical Significance and Correlations with PD-1 Blockade. Molecular Medicine Reports, 14, 1107-1116. [Google Scholar] [CrossRef] [PubMed]
[5] Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
[6] Xue, H., Lan, X., Xue, T., Tang, X., Yang, H., Hu, Z., et al. (2024) PD-1+ T Lymphocyte Proportions and Hospitalized Exacerbation of COPD: A Prospective Cohort Study. Respiratory Research, 25, Article No. 218. [Google Scholar] [CrossRef] [PubMed]
[7] Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
[8] Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000) Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. The Journal of Experimental Medicine, 192, 1027-1034. [Google Scholar] [CrossRef] [PubMed]
[9] Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death. The EMBO Journal, 11, 3887-3895. [Google Scholar] [CrossRef] [PubMed]
[10] Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M. and Saito, T. (2012) Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2. Journal of Experimental Medicine, 209, 1201-1217. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, Q., Bardhan, K., Boussiotis, V.A. and Patsoukis, N. (2021) The PD-1 Interactome. Advanced Biology, 5, e2100758. [Google Scholar] [CrossRef] [PubMed]
[12] Zou, W. (2005) Immunosuppressive Networks in the Tumour Environment and Their Therapeutic Relevance. Nature Reviews Cancer, 5, 263-274. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. [Google Scholar] [CrossRef] [PubMed]
[14] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine, 366, 2443-2454. [Google Scholar] [CrossRef] [PubMed]
[15] 郑忠青, 焦国慧, 郭丽萍, 王邦茂, 周璐. PD-1通路调控淋巴细胞分化参与自身免疫性疾病发生的研究进展[J]. 天津医科大学学报, 2016, 22(6): 541-543.
[16] 何红霞, 范恒, 杨佳. PD-1/PD-L1在自身免疫性疾病中作用的研究进展[J]. 华中科技大学学报(医学版), 2021, 50(5): 664-668.
[17] Curnock, A.P., Bossi, G., Kumaran, J., Bawden, L.J., Figueiredo, R., Tawar, R., et al. (2021) Cell-Targeted PD-1 Agonists That Mimic PD-L1 Are Potent T Cell Inhibitors. JCI Insight, 6, e152468. [Google Scholar] [CrossRef] [PubMed]
[18] Mark, N.M., Kargl, J., Busch, S.E., Yang, G.H.Y., Metz, H.E., Zhang, H., et al. (2018) Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 197, 325-336. [Google Scholar] [CrossRef] [PubMed]
[19] Ritzmann, F., Borchardt, K., Vella, G., Chitirala, P., Angenendt, A., Herr, C., et al. (2021) Blockade of PD-1 Decreases Neutrophilic Inflammation and Lung Damage in Experimental COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology, 320, L958-L968. [Google Scholar] [CrossRef] [PubMed]
[20] 张鸽, 常美佳, 黄嘉楠, 周建, 宋元林, 白春学, 洪群英. KGF-2对COPD小鼠保护性作用的免疫学研究[J]. 复旦学报(医学版), 2018, 45(5): 638-643.
[21] Barnes, P.J. (2016) Inflammatory Mechanisms in Patients with Chronic Obstructive Pulmonary Disease. Journal of Allergy and Clinical Immunology, 138, 16-27. [Google Scholar] [CrossRef] [PubMed]
[22] Xin, X.F., Zhao, M., Li, Z.L., Song, Y. and Shi, Y. (2007) Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 in Induced Sputum in Patients with Asthma and Chronic Obstructive Pulmonary Disease and Their Relationship to Airway Inflammation and Airflow Limitation. Chinese Journal of Tuberculosis and Respiratory Diseases, 30, 192-196.
[23] Mathioudakis, A.G., Janssens, W., Sivapalan, P., Singanayagam, A., Dransfield, M.T., Jensen, J.S., et al. (2020) Acute Exacerbations of Chronic Obstructive Pulmonary Disease: In Search of Diagnostic Biomarkers and Treatable Traits. Thorax, 75, 520-527. [Google Scholar] [CrossRef] [PubMed]
[24] Barnes, P.J. (2019) Inflammatory Endotypes in COPD. Allergy, 74, 1249-1256. [Google Scholar] [CrossRef] [PubMed]
[25] Ye, C., Yuan, L., Wu, K., Shen, B. and Zhu, C. (2023) Association between Systemic Immune-Inflammation Index and Chronic Obstructive Pulmonary Disease: A Population-Based Study. BMC Pulmonary Medicine, 23, Article No. 295. [Google Scholar] [CrossRef] [PubMed]
[26] Hogg, J.C., Chu, F., Utokaparch, S., Woods, R., Elliott, W.M., Buzatu, L., et al. (2004) The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 350, 2645-2653. [Google Scholar] [CrossRef] [PubMed]
[27] Kirkham, P.A. and Barnes, P.J. (2013) Oxidative Stress in COPD. Chest, 144, 266-273. [Google Scholar] [CrossRef] [PubMed]
[28] Sharma, M., Joshi, S., Banjade, P., Ghamande, S.A. and Surani, S. (2024) Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed. The Open Respiratory Medicine Journal, 18, e18743064279064. [Google Scholar] [CrossRef] [PubMed]
[29] 徐影, 云俊杰, 王健. 慢阻肺急性加重期患者外周血T细胞中PD-1/PD-L1的表达水平及意义[J]. 热带医学杂志, 2019, 19(5): 641-644.
[30] 张知远, 金海珍, 余欣颐. 慢阻肺急性加重期患者外周血T细胞中PD-1/PD-L1的表达及意义[J]. 中华全科医学, 2020, 18(3): 419-422+426.
[31] Wherry, E.J. (2011) T Cell Exhaustion. Nature Immunology, 12, 492-499. [Google Scholar] [CrossRef] [PubMed]
[32] Zheng, H., Liu, X., Zhang, J., Rice, S.J., Wagman, M., Kong, Y., et al. (2016) Expression of PD-1 on CD4+ T Cells in Peripheral Blood Associates with Poor Clinical Outcome in Non-Small Cell Lung Cancer. Oncotarget, 7, 56233-56240. [Google Scholar] [CrossRef] [PubMed]
[33] Kalathil, S.G., Lugade, A.A., Pradhan, V., Miller, A., Parameswaran, G.I., Sethi, S., et al. (2014) T-Regulatory Cells and Programmed Death 1+ T Cells Contribute to Effector T-Cell Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 190, 40-50. [Google Scholar] [CrossRef] [PubMed]
[34] Asano, T., Meguri, Y., Yoshioka, T., Kishi, Y., Iwamoto, M., Nakamura, M., et al. (2017) PD-1 Modulates Regulatory T-Cell Homeostasis during Low-Dose Interleukin-2 Therapy. Blood, 129, 2186-2197. [Google Scholar] [CrossRef] [PubMed]
[35] Chen, J., Wang, X., Schmalen, A., Haines, S., et al. (2023) Antiviral CD8+ T-Cell Immune Responses Are Impaired by Cigarette Smoke and in COPD. European Respiratory Journal, 62, Article 2201374.
[36] Tinoco, R., Carrette, F., Barraza, M.L., Otero, D.C., Magaña, J., Bosenberg, M.W., et al. (2016) PSGL-1 Is an Immune Checkpoint Regulator That Promotes T Cell Exhaustion. Immunity, 44, Article 1470. [Google Scholar] [CrossRef] [PubMed]
[37] Xiong, X.F., Zhu, M., Wu, H.X., Wu, Z.H., et al. (2025) T-Cell Immune Status in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Case-Control Study. Frontiers in Medicine, 12, Article 1433844. [Google Scholar] [CrossRef] [PubMed]
[38] Biton, J., Ouakrim, H., Dechartres, A., Alifano, M., Mansuet-Lupo, A., Si, H., et al. (2018) Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 198, 928-940. [Google Scholar] [CrossRef] [PubMed]
[39] Freeman, C.M., Martinez, C.H., Todt, J.C., Martinez, F.J., Han, M.K., Thompson, D.L., et al. (2015) Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Associated with Decreased CD4+ & CD8+ T Cells and Increased Growth & Differentiation Factor-15 (GDF-15) in Peripheral Blood. Respiratory Research, 16, Article No. 94. [Google Scholar] [CrossRef] [PubMed]
[40] Xue, W., Ma, J., Li, Y. and Xie, C. (2022) Role of CD4+ T and CD8+ T Lymphocytes-Mediated Cellular Immunity in Pathogenesis of Chronic Obstructive Pulmonary Disease. Journal of Immunology Research, 2022, 1-9. [Google Scholar] [CrossRef] [PubMed]
[41] Lee, J.W., Chun, W., Lee, H.J., Min, J.H., et al. (2021) The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases. Cells, 10, Article 897. [Google Scholar] [CrossRef] [PubMed]
[42] Antonangeli, F., Natalini, A., Garassino, M.C., Sica, A., Santoni, A. and Di Rosa, F. (2020) Regulation of PD-L1 Expression by NF-κB in Cancer. Frontiers in Immunology, 11, Article 584626. [Google Scholar] [CrossRef] [PubMed]
[43] Zhang, Y., Aldo, P., You, Y., Ding, J., Kaislasuo, J., Petersen, J.F., et al. (2020) Trophoblast-Secreted Soluble-PD-L1 Modulates Macrophage Polarization and Function. Journal of Leukocyte Biology, 108, 983-998. [Google Scholar] [CrossRef] [PubMed]
[44] Fang, Q., Stehr, A.M., Naschberger, E., Knopf, J., Herrmann, M. and Stürzl, M. (2022) No NETs No TIME: Crosstalk between Neutrophil Extracellular Traps and the Tumor Immune Microenvironment. Frontiers in Immunology, 13, Article 1075260. [Google Scholar] [CrossRef] [PubMed]
[45] Barnes, P.J. (2008) Immunology of Asthma and Chronic Obstructive Pulmonary Disease. Nature Reviews Immunology, 8, 183-192. [Google Scholar] [CrossRef] [PubMed]
[46] Hogg, J.C. and Timens, W. (2009) The Pathology of Chronic Obstructive Pulmonary Disease. Annual Review of Pathology: Mechanisms of Disease, 4, 435-459. [Google Scholar] [CrossRef] [PubMed]
[47] Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. [Google Scholar] [CrossRef] [PubMed]
[48] Chen, L. and Han, X. (2015) Anti-PD-1/PD-l1 Therapy of Human Cancer: Past, Present, and Future. Journal of Clinical Investigation, 125, 3384-3391. [Google Scholar] [CrossRef] [PubMed]
[49] McKendry, R.T., Spalluto, C.M., Burke, H., Nicholas, B., Cellura, D., Al-Shamkhani, A., et al. (2016) Dysregulation of Antiviral Function of CD8+ T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis. American Journal of Respiratory and Critical Care Medicine, 193, 642-651. [Google Scholar] [CrossRef] [PubMed]
[50] Helou, D.G., Shafiei-Jahani, P., Lo, R., Howard, E., Hurrell, B.P., Galle-Treger, L., et al. (2020) PD-1 Pathway Regulates ILC2 Metabolism and PD-1 Agonist Treatment Ameliorates Airway Hyperreactivity. Nature Communications, 11, Article No. 3998. [Google Scholar] [CrossRef] [PubMed]
[51] Galván Morales, M.A., Montero-Vargas, J.M., Vizuet-de-Rueda, J.C. and Teran, L.M. (2021) New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. International Journal of Molecular Sciences, 22, Article 11898. [Google Scholar] [CrossRef] [PubMed]
[52] 中华医学会呼吸病学分会, 中国抗癌协会肿瘤呼吸病专业委员会, 北京肿瘤防治研究会. 免疫检查点抑制剂相关肺炎诊治和管理专家共识(2025) [J]. 中华结核和呼吸杂志, 2025, 48(4): 329-343.

为你推荐